ABU DHABI, UAE, June 7, 2024 /PRNewswire/ — At BIO 2024 International Convention, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Novartis Middle East FZE, a global pharmaceutical company. Under the terms of the MoU, the entities will work together to advance solutions in multiple therapeutic areas. The two priority focus areas include advancing clinical genomics research for real-world evidence (RWE) and generating and disseminating evidence to support the understanding of radioligand therapy (RLT) for cancer patients.
In the presence of Thierry Diagana, Head of Global Health and California Sites Head at Novartis Biomedical Research, the MoU was signed by Dr Asma Ibrahim Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH and Ibrahim Aqel, Head of Government Affairs and Value & Access – Gulf at Novartis.
This collaboration will utilise Abu Dhabi’s genomics expertise and its future-forward, agile regulatory framework research hub to collaborate on future clinical research and the generation of RWE. This will include exploration of innovative solutions and genomics research in oncology, cardiovascular disease, and neuroscience. The two will also work together to generate and disseminate evidence to support the awareness and understanding of RLT – a form of precision nuclear medicine that may recognise and treat disease in patients with advanced cancers – with key stakeholders.
Dr. Asma Ibrahim Al Mannaei said: “Novartis has been a long-standing partner to the Department of Health, and we are proud to explore these new areas of opportunity to collaborate for the ultimate benefit of patients in the region and beyond. We believe that this
partnership will allow us to further accelerate the field of personalised and precision medicine across important therapeutic areas. As we continue to establish Abu Dhabi as a hub for global life science and a centre for innovative research, we are excited to work in synergy with our strategic partners, and combine our expertise in the pursuit of common goals.”
Novartis and DoH will explore innovative solutions for local and regional health needs. This will include supporting the Emirati Genome Programme by collaborating to raise awareness of genetic and rare diseases. The final focus area is supporting the further improvement of the Health Technology Assessment through facilitated partnership and shared best practice.
Mohamed Ezz Eldin Head of Gulf countries for Novartis, said: “We are thrilled to announce our collaboration with the Department of Health – Abu Dhabi through the signing of this Memorandum of Understanding. This partnership represents a significant milestone in advancing research and innovation in healthcare, particularly in the fields of oncology, cardiovascular diseases, and neuroscience. Novartis is committed to supporting the development of clinical research capabilities in Abu Dhabi, generating real-world evidence, and raising awareness about radioligand therapy. We look forward to working closely with the Department of Health – Abu Dhabi to drive innovation and enhance the Health Technology Assessment capabilities in the region. Our goal is to contribute to personalized and precision medicine, ultimately improving patient outcomes”
Led by the Department of Health – Abu Dhabi (DoH), a high-profile Abu Dhabi delegation headed by His Excellency Mansoor Ibrahim Al Mansoori, Chairman of the DoH, is visiting the United States of America (USA) between May 29th,2024 and June 5th,2024 to showcase the Emirate’s partnership opportunities and explore collaboration with leading organizations in Research and Development (R&D), manufacturing and innovation. Kicking-off in Philadelphia, delegates have met with existing and new partners to foster collaboration with leading education research institutions, governmental bodies and health-tech giants. The transnational mission has culminated in San Diego, coinciding with Abu Dhabi’s participation at BIO International Convention 2024 to exhibit the Emirate’s growth and development of its biotechnology industry.
The participation has witnessed in-depth discussions, shared insights and expertise as well as explored collaborations in health-tech, life science and innovation.
Photo – https://mma.prnewswire.com/media/2432775/DoH_and_Novartis.jpg
View original content:https://www.prnewswire.co.uk/news-releases/department-of-health–abu-dhabi-and-novartis-to-partner-to-advance-genomics-research-in-oncology-and-beyond-302166655.html
